Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

4.45USD
21 Aug 2019
Change (% chg)

-- (--)
Prev Close
$4.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
266,442
52-wk High
$5.36
52-wk Low
$2.58

Latest Key Developments (Source: Significant Developments)

Biodelivery Sciences International Files For Mixed Shelf Of Up to $125 Mln
Monday, 29 Jul 2019 05:49pm EDT 

July 29 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL INC FILES FOR MIXED SHELF OF UPTO $125 MILLION - SEC FILING.BIODELIVERY SCIENCES INTERNATIONAL INC SAYS IN ADDITION, SELLING STOCKHOLDER OFFERING 12.8 MILLION SHARES OF CO'S COMMON STOCK.  Full Article

Biodelivery Sciences International Will Not Receive Any Of Proceeds From Sale Of Shares Of Common Stock By Selling Stockholder
Wednesday, 10 Apr 2019 04:07pm EDT 

April 10 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.BIODELIVERY SCIENCES INTERNATIONAL INC - BDSI WILL NOT RECEIVE ANY OF PROCEEDS FROM SALE OF SHARES OF COMMON STOCK BY SELLING STOCKHOLDER..  Full Article

Biodelivery Sciences Acquires U.S. Commercial Rights To Symproic
Wednesday, 10 Apr 2019 04:05pm EDT 

April 10 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES ACQUIRES U.S. COMMERCIAL RIGHTS TO SYMPROIC®.BIODELIVERY SCIENCES INTERNATIONAL INC - TOTAL 2019 COMPANY NET SALES EXPECTED TO BE $92-$100 MILLION WITH SYMPROIC NET SALES OF $7-$9 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - WILL PAY SHIONOGI, INC., AN INITIAL PAYMENT OF $20 MILLION AND AN ADDITIONAL $10 MILLION IN SIX MONTHS.BIODELIVERY SCIENCES INTERNATIONAL INC - SHIONOGI IS ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS BASED ON NET SALES OF SYMPROIC.BIODELIVERY SCIENCES INTERNATIONAL INC - COMPANY HAS REAFFIRMED ITS EXPECTATION TO BECOME OPERATING CASH FLOW POSITIVE BY END OF 2019..BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECTS LONG-TERM NET SALES POTENTIAL OF ITS PRODUCT PORTFOLIO TO BE IN RANGE OF $325 - $400 MILLION.BIODELIVERY SCIENCES INTERNATIONAL INC - EXPECT TO SEE AN ACCRETIVE CONTRIBUTION TO CASH FLOW IN FIRST HALF OF 2020 FROM SYMPROIC.  Full Article

Biodelivery Sciences Says On March 1, Bdsi Filed Complaint For Patent Infringement In Delaware
Monday, 4 Mar 2019 08:13am EST 

March 4 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL - ON MARCH 1, 2019, BDSI FILED A COMPLAINT FOR PATENT INFRINGEMENT IN DELAWARE - SEC FILING.BIODELIVERY SCIENCES INTERNATIONAL - COMPLAINT WAS FILED AGAINST CHEMO RESEARCH, S.L., INSUD PHARMA S.L., INTELGENX CORP., AND INTELGENX TECHNOLOGIES.BIODELIVERY SCIENCES INTERNATIONAL - BELIEVES THAT IT WILL BE ABLE TO PREVAIL IN PATENT INFRINGEMENT LAWSUIT.  Full Article

Biodelivery Sciences International Files For Mixed Shelf Of Up To $150 Mln
Friday, 9 Nov 2018 09:46am EST 

Nov 9 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES INTERNATIONAL INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

BioDelivery Sciences Announces Agreement With Broadfin Capital On Comprehensive Plan To Strengthen Business
Thursday, 17 May 2018 08:01am EDT 

May 17 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES ANNOUNCES AGREEMENT WITH BROADFIN CAPITAL ON COMPREHENSIVE PLAN TO STRENGTHEN BUSINESS.BIODELIVERY SCIENCES INTERNATIONAL INC - $50 MILLION EQUITY FINANCING IS BEING LED BY BROADFIN CAPITAL.BIODELIVERY SCIENCES INTERNATIONAL - HAS ENTERED INTO AGREEMENT WITH AFFILIATE OF BROADFIN CAPITAL TO RECONSTITUTE BDSI'S BOARD.BIODELIVERY SCIENCES INTERNATIONAL INC - DEALS EXTEND BDSI'S CASH RUNWAY THROUGH 2020.BIODELIVERY SCIENCES INTERNATIONAL INC - AMENDS SENIOR CREDIT FACILITY WITH CRG.BIODELIVERY SCIENCES INTERNATIONAL INC - THREE NEW INDEPENDENT DIRECTORS SELECTED BY BROADFIN ADDED TO BOARD.BIODELIVERY SCIENCES - UNDER AGREEMENT, AT CLOSING, BROADFIN MANAGING PARTNER KEVIN KOTLER TO JOIN CO'S BOARD, WITH TODD DAVIS, PETER GREENLEAF.BIODELIVERY SCIENCES INTERNATIONAL INC - FOUR CURRENT INDEPENDENT DIRECTORS RETIRING.BIODELIVERY SCIENCES INTERNATIONAL INC - AMENDS SENIOR CREDIT FACILITY WITH CRG, WHICH INCLUDES PUSHING OUT PRINCIPAL DEBT REPAYMENT TO 2021.BIODELIVERY SCIENCES - BROADFIN WILL WITHDRAW NOTICE OF NOMINATION OF PERSONS FOR ELECTION AS DIRECTORS AT BDSI'S STOCKHOLDERS MEETING.BIODELIVERY SCIENCES INTERNATIONAL INC - BROADFIN ALSO AGREED TO VOTE ITS SHARES AT ANNUAL MEETING FOR BDSI'S DIRECTOR NOMINEES.BIODELIVERY SCIENCES INTERNATIONAL - BROADFIN ALSO AGREED TO CERTAIN CUSTOMARY STANDSTILL RESTRICTIONS.  Full Article

BioDelivery Sciences Appoints Herm Cukier As CEO
Monday, 7 May 2018 09:00am EDT 

May 7 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES APPOINTS HERM CUKIER AS CHIEF EXECUTIVE OFFICER.BIODELIVERY SCIENCES INTERNATIONAL INC - FORMER PRESIDENT AND CEO MARK A. SIRGO WILL CONTINUE HIS ROLE AS VICE CHAIRMAN OF BOARD OF DIRECTORS.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
Monday, 27 Nov 2017 07:00am EST 

Nov 27 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍BELBUCA WILL BE ADDED TO FORMULARY AS A TIER 1 LONG-ACTING OPIOID WITHOUT RESTRICTIONS​.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍CHANGES TO FORMULARY WILL GO INTO EFFECT APRIL 1, 2018​.  Full Article

BioDelivery Sciences reports Q3 loss per share $0.21
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - BioDelivery Sciences International Inc :BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.21.Q3 revenue $11.3 million versus I/B/E/S view $9.4 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article